Global Radioimmunotherapy Supply, Demand and Key Producers, 2026-2032

The global Radioimmunotherapy market size is expected to reach $ 6998 million by 2032, rising at a market growth of 14.3% CAGR during the forecast period (2026-2032).

Radioimmunotherapy (RIT) is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.

Global key Companies of Radioimmunotherapy include Novartis, Bayer, etc. The top two players hold a share over 98%. North America is the largest market, with a share about 62%, followed by Europe and Asia-Pacific, with the share about 29% and 8%. In terms of product type, Beta-emitting occupy the largest share of the total market, about 90%.

This report studies the global Radioimmunotherapy demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Radioimmunotherapy, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Radioimmunotherapy that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Radioimmunotherapy total market, 2021-2032, (USD Million)

Global Radioimmunotherapy total market by region & country, CAGR, 2021-2032, (USD Million)

U.S. VS China: Radioimmunotherapy total market, key domestic companies, and share, (USD Million)

Global Radioimmunotherapy revenue by player, revenue and market share 2021-2026, (USD Million)

Global Radioimmunotherapy total market by Type, CAGR, 2021-2032, (USD Million)

Global Radioimmunotherapy total market by Application, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global Radioimmunotherapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, Gilead Sciences, Clarity Pharmaceuticals, Curasight, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Radioimmunotherapy market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Radioimmunotherapy Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Radioimmunotherapy Market, Segmentation by Type:
Beta-emitting
Targeted Alpha Therapy

Global Radioimmunotherapy Market, Segmentation by Application:
Solid Tumor
Non Hodgkin Lymphoma

Companies Profiled:
Bayer
Novartis
Lantheus
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Curium Pharmaceuticals
Gilead Sciences
Clarity Pharmaceuticals
Curasight
Nordic Nanovector
Philogen
RadioMedix
Telix Pharmaceuticals
Orano Med
Actinium Pharmaceuticals
Y-mAbs Therapeutics
Fusion Pharmaceuticals

Key Questions Answered

1. How big is the global Radioimmunotherapy market?

2. What is the demand of the global Radioimmunotherapy market?

3. What is the year over year growth of the global Radioimmunotherapy market?

4. What is the total value of the global Radioimmunotherapy market?

5. Who are the Major Players in the global Radioimmunotherapy market?

6. What are the growth factors driving the market demand? Show more